热门资讯> 正文
Jazz，AbCellera交易开发T细胞参与多特异性抗体
2026-06-17 19:47
- Jazz Pharmaceuticals (JAZZ) and AbCellera (ABCL) have inked an agreement that could be worth up to $848M to the latter company to develop next-generation T-cell engaging multispecific antibodies.
- The deal centers around AbCellera's antibody discovery engine to discover candidates for gastrointestinal cancers and other solid tumors.
- Terms call for AbCellera to receive $56M upfront and up to $792M in milestone payments and potential option fees.
- Also, AbCellera will conduct discovery and early-stage research for two programs and has a commitment to begin a third program within a year. Jazz has an option with each research program. If exercised along with payment of an option fee, it will have an exclusive, worldwide right to commercialize those programs.
More on Jazz Pharmaceuticals, AbCellera
- AbCellera: An AI-Era Antibody Platform Trading For Little More Than Its Cash
- AbCellera: Q3 Hot Flashes Data Drop Aside, This Stock Is A Difficult Sell
- AbCellera Biologics Inc. (ABCL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
- Jazz Pharma announces late-stage trial setback for lung cancer therapy
- These low-priced stocks are flashing overbought signals
推荐文章
港股周报 | 市场风格切换！存储、光通信股暴跌，科指反弹近6%；花旗称科网股估值极具吸引力；创新药、机器人概念飙涨
一周IPO | 史上最大ADR来袭！SK海力士或下周五登陆美股；16只新股即将上市！“今年最贵新股”鼎泰高科火热招股中
年中盘点 | 存储概念“强者恒强”！闪迪年内狂飙858%霸榜美股升幅Top10，康宁势将成为下半年最大黑马？
一周财经日历 | 美联储会议纪要重磅来袭；SK海力士拟7月10日登陆美股；智谱、MiniMax限售股将解禁
华盛早报 | 美股冰火两重天！道指狂飙近600点，存储却遭恐慌性抛售；“大空头”Burry唱空美股半导体面临30%回调
7月3日外盘头条：特朗普2025年交易逾2.1万笔 霍尔木兹海峡不复往日 微软计划8月推出Copilot全端整合产品
美股前瞻 | 美国6月非农大幅低于预期！纳指期货转涨至0.5%；马斯克称特斯拉机器人产线或已就绪；英伟达祭出AI工厂分成模式
华盛早报 | AI硬件股集体“熄火”！闪迪、美光暴跌10%，韩股开盘即熔断；苹果酝酿采购中国存储芯片
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
